Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study

This study aimed to investigate the efficacy and safety of apatinib plus programmed cell death protein 1 (PD-1) blockades for patients with metastatic colorectal cancer (CRC) who were refractory to the standard regimens. In this retrospective study, patients with metastatic CRC who received apatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shenglong, Zheng, Hao, Ge, Qinghong, Xia, Shuli, Zhang, Ke, Wang, Chunjing, Wang, Fujing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Cancer Prevention 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564635/
https://www.ncbi.nlm.nih.gov/pubmed/37830117
http://dx.doi.org/10.15430/JCP.2023.28.3.106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564635/
https://www.ncbi.nlm.nih.gov/pubmed/37830117
http://dx.doi.org/10.15430/JCP.2023.28.3.106

Ejemplares similares